Clinical Trial Detail

NCT ID NCT02581930
Title Ibrutinib in Treating Patients With Refractory Stage IV Cutaneous Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

skin melanoma

Therapies

Ibrutinib

Age Groups: adult

No variant requirements are available.